Monopar Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Monopar Therapeutics has a total shareholder equity of $4.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $6.1M and $1.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$6.02m |
Equity | US$4.95m |
Total liabilities | US$1.12m |
Total assets | US$6.07m |
Recent financial health updates
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully
Aug 13Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?
Feb 27Recent updates
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully
Aug 13Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?
Feb 27Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?
Mar 02We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully
Nov 16Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of Validive
Oct 05We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate
Jul 30Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans
Mar 28We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely
Jul 15Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation
Mar 26Monopar nabs U.S. patent covering camsirubicin
Dec 22Monopar Therapeutics selects targeted immuno-therapeutic candidate for COVID-19
Dec 10Monopar launches validive mid-stage study in chemo-induced oral mucositis
Dec 08Monopar Therapeutics EPS beats by $0.02
Nov 12Financial Position Analysis
Short Term Liabilities: MNPR's short term assets ($6.1M) exceed its short term liabilities ($1.1M).
Long Term Liabilities: MNPR has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: MNPR is debt free.
Reducing Debt: MNPR had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MNPR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MNPR is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 18:35 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Monopar Therapeutics Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Brian Kemp Dolliver | Brookline Capital Markets |
Kumaraguru Raja | Brookline Capital Markets |
Sean Lee | H.C. Wainwright & Co. |